MAPT and Brain atrophy: Among all, five biomarkers are currently considered more powerful, including decreased CSF Aβ42, increased CSF tau, decreased fluorodeoxyglucose uptake on PET (FDG-PET), PET amyloid imaging, and brain atrophy on structural magnetic resonance imaging (MRI) (Jack et al., 2010; Dubois et al., 2014).